Alterity Therapeutics (ATHE) Operating Expenses (2014 - 2025)
Alterity Therapeutics (ATHE) posted quarterly Operating Expenses of -$12.7 million for Q4 2025, down 47.18% year-over-year from -$24.0 million in Q4 2024, and down 47.18% quarter-over-quarter from -$8.6 million in Q4 2024.
Alterity Therapeutics (ATHE) Operating Expenses (2014 - 2025) Analysis & Trends
Alterity Therapeutics' Operating Expenses history runs 11 years deep, the most recent figure standing at -$12.7 million for Q4 2025.
- In Q4 2025, Operating Expenses fell 47.18% year-over-year to -$12.7 million; the TTM figure through Dec 2025 stood at -$21.3 million (down 9.34% YoY), while the FY2025 annual figure was $12.7 million, down 100.0% from the prior year.
- Operating Expenses for Q4 2025 stood at -$12.7 million, down from -$8.6 million in the prior quarter.
- The five-year high for Operating Expenses was -$8.6 million in Q4 2024, with the low at -$12.7 million in Q4 2025.
- The 5-year median for Operating Expenses is -$11.3 million (2022), against an average of -$11.0 million.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses increased 20.68% in 2024, then plunged 47.18% in 2025.
- Alterity Therapeutics' Operating Expenses stood at -$11.5 million in 2021, then climbed by 2.0% to -$11.3 million in 2022, then rose by 3.77% to -$10.8 million in 2023, then climbed by 20.68% to -$8.6 million in 2024, then sank by 47.18% to -$12.7 million in 2025.
- Business Quant data shows ATHE's Operating Expenses at -$12.7 million in Q4 2025, -$8.6 million in Q4 2024, and -$10.8 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 541.02 Mn |
| 10 | Alterity Therapeutics | 49.04 Mn | 16.74 Mn | - | -12.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.66 Mn |
| Dec 31, 2024 | -8.60 Mn |
| Dec 31, 2023 | -10.84 Mn |
| Dec 31, 2022 | -11.27 Mn |
| Dec 31, 2021 | -11.50 Mn |
| Dec 31, 2019 | 4.32 Mn |
| Dec 31, 2018 | -5.50 Mn |
| Jun 30, 2018 | 108.95 Mn |
| Dec 31, 2017 | -3.05 Mn |
| Dec 31, 2016 | 4.63 Mn |
| Dec 31, 2015 | 4.11 Mn |
| Dec 31, 2014 | 4.00 Mn |